Literature DB >> 11502176

A novel family of hairpin peptides that inhibit IgE activity by binding to the high-affinity IgE receptor.

G R Nakamura1, M A Starovasnik, M E Reynolds, H B Lowman.   

Abstract

A family of structured peptides that bind to FcepsilonRIalpha, the alpha-chain of the high-affinity receptor for IgE, has been identified. Binding selections using FcepsilonRIalpha and polyvalent peptide-phage libraries yielded a dominant 18-residue peptide-phage clone, as well as related sequences that did not resemble fragments of IgE. Synthetic peptides based on these sequences inhibited IgE binding to its receptor, and were found by NMR analysis to adopt a stable beta-hairpin structure in solution. Optimized peptides with micromolar receptor affinity exhibited high stability in biological fluids and inhibited cellular histamine release in an in vitro bioassay of IgE activity. The structure-activity relationships of these peptides, which are less than 1% of the size of IgE, suggest an overlap between their binding site and that of IgE on FcepsilonRI. Thus, the peptides demonstrate that blocking a small epitope on this receptor chain is sufficient to block IgE activity. Such structured peptides represent a possible starting point for the design of novel antagonists, and offer the potential for testing in vivo a new approach for treating allergic disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11502176     DOI: 10.1021/bi0109360

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  9 in total

1.  Stable "zeta" peptides that act as potent antagonists of the high-affinity IgE receptor.

Authors:  Gerald R Nakamura; Mark E Reynolds; Yvonne M Chen; Melissa A Starovasnik; Henry B Lowman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-05       Impact factor: 11.205

2.  An IgE receptor mimetic peptide (PepE) protects mice from IgE mediated anaphylaxis.

Authors:  Joseph S Zhou; Annamaria Sandomenico; Valeria Severino; Oliver T Burton; Alanna Darling; Hans C Oettgen; Menotti Ruvo
Journal:  Mol Biosyst       Date:  2013-11

Review 3.  Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond.

Authors:  P Mark Hogarth; Geoffrey A Pietersz
Journal:  Nat Rev Drug Discov       Date:  2012-03-30       Impact factor: 84.694

Review 4.  IgE and mast cells in allergic disease.

Authors:  Stephen J Galli; Mindy Tsai
Journal:  Nat Med       Date:  2012-05-04       Impact factor: 53.440

5.  Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells.

Authors:  Alexander Eggel; Günther Baravalle; Gabriel Hobi; Beomkyu Kim; Patrick Buschor; Patrik Forrer; Jeoung-Sook Shin; Monique Vogel; Beda M Stadler; Clemens A Dahinden; Theodore S Jardetzky
Journal:  J Allergy Clin Immunol       Date:  2014-03-15       Impact factor: 10.793

6.  Anti-ids in allergy: timeliness of a classic concept.

Authors:  Julia Wallmann; Isabella Pali-Schöll; Erika Jensen-Jarolim
Journal:  World Allergy Organ J       Date:  2010-06       Impact factor: 4.084

Review 7.  Small and Simple, yet Sturdy: Conformationally Constrained Peptides with Remarkable Properties.

Authors:  Krištof Bozovičar; Tomaž Bratkovič
Journal:  Int J Mol Sci       Date:  2021-02-05       Impact factor: 5.923

8.  Identification of cyclic peptides able to mimic the functional epitope of IgG1-Fc for human Fc gammaRI.

Authors:  Stephane Bonetto; Loredana Spadola; Andrew G Buchanan; Lutz Jermutus; John Lund
Journal:  FASEB J       Date:  2008-10-28       Impact factor: 5.191

Review 9.  Regulation of Trafficking and Signaling of the High Affinity IgE Receptor by FcεRIβ and the Potential Impact of FcεRIβ Splicing in Allergic Inflammation.

Authors:  Greer K Arthur; Glenn Cruse
Journal:  Int J Mol Sci       Date:  2022-01-12       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.